Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1508-1517

  Krishan, Awtar ^a,c   Sridhar, Kasi S ^a   Mou, Caihong ^a   Stein, Wilfred D ^b   Lyubimov, Elena ^b   Hu, Yang Ping ^a   Fernandez, Hugo ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DIPYRIDAMOLE; DOXORUBICIN; PROCHLORPERAZINE; TRITIUM; VERAPAMIL;

ANIMAL CELL; ARTICLE; COLON CANCER; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL SURVIVAL; COLONIC NEOPLASMS; CULTURE MEDIA; DAUNORUBICIN; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; NEOPLASMS; PLASMA; PROCHLORPERAZINE; TUMOR CELLS, CULTURED;

EID: 0034051423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Deffie, A. M., Alam, T., Seneviratne, C., Beenken, S. W., Batra, J. K., Shea, T. C., Henner, W. D., and Goldenberg, G. J. Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res., 48: 3595-3602, 1988.
2. Nair, S., Singh, S. V., Samy, T. S. A., and Krishan, A. Anthracycline resistance in murine leukemic P388 cells: role of drug efflux and glutathione related enzymes. Biochem. Pharmacol., 39: 723-728, 1990.
3. Tsuruo, T., Iida. H., Nojiri, M., Tsukagoshi, S., and Sakurai, Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res., 43: 2905-2910, 1983.
4. Ganapathi, R., Grabowski, D., Rouse, W., and Riegler, F. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (Adriamycin)-resistant P388 mouse leukemia cells. Cancer Res., 44: 5056-5061, 1984.
5. Krishan, A., Sauerteig, A., and Wellham, L. Flow cytometric studies on modulation of cellular Adriamycin retention by phenothiazines. Cancer Res., 45: 1046-1051, 1985.
6. Ozols, R. F., Cunnion, R. E., Klecker, R. W., Jr., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., and Young, R. C. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol., 5: 641-647, 1987.
7. Miller, R. L., Bukowski, R. M., Budd, G. T., Purvis, J., Weick, J. K., Shepard, K., Midha, K. K., and Ganapathi, R. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a Phase I/II trial. J. Clin. Oncol., 6: 880-888, 1988.
8. Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, T. M., Laufman, L. R., Weiss, G. R., and Bonnet, J. D. A Phase II randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer (Phila.), 75: 815-820, 1995.
9. Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., Beketic-Oreskovic, L., and Chen, G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol., 40 (Suppl.): S13-S19, 1997.
10. Krishan, A., Sridhar, K. S., Davila, E., Vogel, C., and Stemheim, W. Patterns of anthracycline retention modulation in human tumor cells. Cytometry, 8: 306-314, 1987.
11. Sridhar, K. S., Krishan, A., Samy, T. S. A., Sauerteig, A., Wellham, L. L., McPhee, G., Duncan, R. C., Anac, S. Y., Ardalan, B., and Benedetto, P. W. Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother. Pharmacol., 31: 423-430, 1993.
12. Sridhar, K. S., Krishan, A., Samy, T. S. A., Duncan, R. C., Sauerteig, A., McPhee, G. V., Auguste, M. E., Benedetto, P. W., and Waldman, S. Phase I and pharmacokinetic studies of prochlorperazine 2-hour IV infusion as a doxorubicin efflux blocker. Cancer Chemother. Pharmacol., 34: 377-324, 1994.
13. Sridhar, K. S., Krishan, A., Samy, T. S. A., McPhee, G. V., Sauerteig, A., Ramachandran, C., Benedetto, P. W., and Hussein, A. Study of escalating doses of dipyridarnole (DPL) and fixed dose of doxorubicin (DOX) in refractory cancer patients. Proc. Am. Assoc. Cancer Res., 35: 360, 1994.
14. Hu, X. F., Martin, T. J., Bell, D. R., de Luise, M., and Zalcberg, J. R. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.
15. Lehnert, M., Dalton, W. S., Roe, D., Emerson, S., and Salmon, S. E. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood, 77: 348-354, 1991.
16. Lyubimov, E., Lan, L. B., Pashinsky, I., Ayesh, S., and Stein, W. D. Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anti-Cancer Drugs, 6: 2-35, 1995.
17. Ayesh, S., Shao, S., and Stein, W. D. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta, 1316: 8-18, 1996.
18. Maniar, N., Samy, T. S. A., Krishan, A., and Israel, M. Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells. Biochem. Pharmacol., 37: 1763-1772, 1988.
19. Leibovitz, A. L., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C., and Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res., 36: 4562-4569, 1976.
20. Krishan, A., Sauerteig, A., Andritsch, I., and Wellham, L. Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia(Baltimore), 11: 1138-1146, 1997.
21. Mou, C., Ganju, N., Sridhar, K., and Krishan, A. Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high performance chromatography. J. Chromatogr. B, 703: 217-224, 1997.
22. Gabrielsson, J., and Weiner, D. Pharmacokinetic and Pharmacodynamic Data Analysis Concepts and Applications, Vol. 1, pp. 107-114. Stockholm: Swedish Pharmaceutical Press, 1994.
23. Willson, J. K. V., Fischer, P. H., Tutsch, K., Alberti, D., Simon, K., Hamilton, R. D., Bruggink, J., Koeller, J. M., Tormey, D. C., Earhart, R. H., Ranhosky, A., and Trump, D. L. Phase I clinical trial of a combination of dipyridarnole and acivicin based upon inhibition of nucleoside salvage. Cancer Res., 48: 5585-5590, 1988.
24. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
25. Egorin, M. J., Hildebrand, R. C., Cimino, E. F., and Bachur, N. R. Cytofluorescence localization of Adriamycin and daunorubicin. Cancer Res., 34: 2243-2245, 1974.
26. Scala, S., Akhmed, N., Rao, U. S., Paull, K., Lan, L. B., Dickstein, B., Lee, J. S., Elgemeie, G. H., Stein, W. D., and Bates, S. E. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol., 51: 1024-1033, 1997.
27. Stein, W. D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev., 77: 545-590, 1997.
28. Fitzgerald, G. A. Dipyridamole. N. Engl. J. Med., 316: 1247-1257, 1987.